AIM: To assess serum concentrations of prohepcidin in chronic hepatitis C individuals and evaluate their associations with disease activity and efficacy of pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. METHO...AIM: To assess serum concentrations of prohepcidin in chronic hepatitis C individuals and evaluate their associations with disease activity and efficacy of pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. METHODS: Prohepcidin was measured in sera of 53 chronic hepatitis C patients. Concentrations of prohepcidin and other iron metabolism markers were analyzed at 9 time points before, during and after the end of antiviral therapy. RESULTS: In hepatitis C virus (HCV) genotype 1-infected individuals, a gradual decrease of prohepcidin during antiviral therapy was observed in responders (88.8 ± 14.7 ng/mL before therapy vs 60.6 ± 0.3 ng/mL in the 48th wk, P = 0.04). In contrast, no decrease was observed in non-responders. A similar association was observed in HCV genotype 3a individuals, with a statistically significant decline in serum prohepcidin only in the responder group (99.5 ± 5.2 ng/mL at baseline vs 72.7 ± 6.1 ng/mL in the 24th wk, P = 0.01). Moreover, HCVRNA at week 12 of therapy was positively correlated with baseline (R = 0.63, P < 0.005) and week 12 (R = 0.60, P = 0.01) serum prohepcidin concentrations in HCV genotype 1 infection. CONCLUSION: Successful PEG-IFN/RBV therapy results in a decline of serum prohepcidin concentration in chronic hepatitis C, which may suggest a direct effect of HCV on iron metabolism at the prohormonal level of hepcidin.展开更多
Objective: To study the correlation of serum hepcidin (HEP) and transferrin receptor (sTfR) contents with iron deficiency and micro-inflammatory response in patients with hemodialysis. Methods: Patients undergoing mai...Objective: To study the correlation of serum hepcidin (HEP) and transferrin receptor (sTfR) contents with iron deficiency and micro-inflammatory response in patients with hemodialysis. Methods: Patients undergoing maintenance hemodialysis in the Jingzhou Central Hospital between June 2014 and March 2017 were selected as MHD group, healthy volunteers receiving physical examination during the same period were selected as control group, serum was collected to determine the levels of HEP, sTfR, iron deficiency indexes, inflammatory response indexes and oxidative stress indexes, and the correlation between indicators was analyzed. Results: Serum HEP, sTfR, TNF-α, IL-17, IL-23, NOX2 and MDA levels of MHD group were higher than those of control group while SF, TRF, Aeplin, IL-10, SOD, GSH-P and TAC levels were lower than those of control group;serum Aeplin, IL-10, SOD, GSH-P and TAC levels of MHD group were negatively correlated with SF and TRF levels whereas the TNF-α, IL-17, IL-23, NOX2 and MDA levels were positively correlated with SF and TRF levels. Conclusions: The increase of serum HEP and sTfR in patients with hemodialysis can reflect the degree of iron deficiency and is closely related to the degree of micro-inflammatory response.展开更多
基金Supported by A Scientific Grant from the Medical University in Bialystok, No. 356978-La Polpharma Foundation For Development of Polish Pharmacy and Medicine
文摘AIM: To assess serum concentrations of prohepcidin in chronic hepatitis C individuals and evaluate their associations with disease activity and efficacy of pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. METHODS: Prohepcidin was measured in sera of 53 chronic hepatitis C patients. Concentrations of prohepcidin and other iron metabolism markers were analyzed at 9 time points before, during and after the end of antiviral therapy. RESULTS: In hepatitis C virus (HCV) genotype 1-infected individuals, a gradual decrease of prohepcidin during antiviral therapy was observed in responders (88.8 ± 14.7 ng/mL before therapy vs 60.6 ± 0.3 ng/mL in the 48th wk, P = 0.04). In contrast, no decrease was observed in non-responders. A similar association was observed in HCV genotype 3a individuals, with a statistically significant decline in serum prohepcidin only in the responder group (99.5 ± 5.2 ng/mL at baseline vs 72.7 ± 6.1 ng/mL in the 24th wk, P = 0.01). Moreover, HCVRNA at week 12 of therapy was positively correlated with baseline (R = 0.63, P < 0.005) and week 12 (R = 0.60, P = 0.01) serum prohepcidin concentrations in HCV genotype 1 infection. CONCLUSION: Successful PEG-IFN/RBV therapy results in a decline of serum prohepcidin concentration in chronic hepatitis C, which may suggest a direct effect of HCV on iron metabolism at the prohormonal level of hepcidin.
文摘Objective: To study the correlation of serum hepcidin (HEP) and transferrin receptor (sTfR) contents with iron deficiency and micro-inflammatory response in patients with hemodialysis. Methods: Patients undergoing maintenance hemodialysis in the Jingzhou Central Hospital between June 2014 and March 2017 were selected as MHD group, healthy volunteers receiving physical examination during the same period were selected as control group, serum was collected to determine the levels of HEP, sTfR, iron deficiency indexes, inflammatory response indexes and oxidative stress indexes, and the correlation between indicators was analyzed. Results: Serum HEP, sTfR, TNF-α, IL-17, IL-23, NOX2 and MDA levels of MHD group were higher than those of control group while SF, TRF, Aeplin, IL-10, SOD, GSH-P and TAC levels were lower than those of control group;serum Aeplin, IL-10, SOD, GSH-P and TAC levels of MHD group were negatively correlated with SF and TRF levels whereas the TNF-α, IL-17, IL-23, NOX2 and MDA levels were positively correlated with SF and TRF levels. Conclusions: The increase of serum HEP and sTfR in patients with hemodialysis can reflect the degree of iron deficiency and is closely related to the degree of micro-inflammatory response.
